RGEN REPLIGEN CORP
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 730272 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.8%
TTM net income YoY-779.2%
TTM EPS YoY-1,150.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin53.8%
Operating margin2.3%
Net margin-1.5%
FCF margin13.2%
EBITDA margin11.9%
Returns
ROE-0.6%
ROA-0.4%
ROIC (approx.)0.5%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets28.5%
Debt / equity0.27x
Current ratio9.88x
Interest coverage0.81x
Cash quality & payout
Operating cash flow / net income-11.00x
Accruals ratio-4.8%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $738.26M | $634.44M | $632.36M | $801.54M | $670.53M |
| Cost of revenue | $352.01M | $359.79M | $353.92M | $345.83M | $279.28M |
| Gross profit | $386.25M | $274.64M | $278.44M | $455.71M | $391.25M |
| R&D expense | $54.18M | $43.20M | $42.72M | $43.94M | $34.27M |
| SG&A expense | $290.51M | $263.37M | $218.58M | $215.83M | $183.87M |
| Operating income | $55.17M | -$35.11M | $47.70M | $224.67M | $167.25M |
| Interest expense | $21.51M | $20.73M | $2.50M | $1.16M | $11.28M |
| Pretax income | $62.38M | -$27.04M | $56.71M | $219.14M | $153.54M |
| Income tax | $13.49M | -$1.52M | $21.11M | $33.18M | $25.25M |
| Net income | $48.89M | -$25.51M | $35.60M | $185.96M | $128.29M |
| EBITDA | $133.91M | $34.56M | $116.26M | $275.65M | $205.70M |
| EPS (basic) | 0.87 | -0.46 | 0.64 | 3.35 | 2.33 |
| EPS (diluted) | 0.86 | -0.46 | 0.63 | 3.24 | 2.24 |
| Weighted avg. shares (diluted) | 56,561 | 55,937 | 56,377 | 57,455 | 57,264 |
| Balance sheet | |||||
| Cash & equivalents | $566.02M | $757.36M | $751.32M | $523.46M | $603.81M |
| Short-term investments | $201.61M | $0 | — | — | — |
| Receivables | $158.59M | $134.12M | $124.16M | $116.25M | $117.42M |
| Inventory | $170.46M | $142.96M | $202.32M | $238.28M | $184.49M |
| Current assets | $1.14B | $1.07B | $1.11B | $998.12M | $931.68M |
| PP&E, net | $186.61M | $197.74M | $207.44M | $190.67M | $124.96M |
| Goodwill | $1.11B | $1.03B | $987.12M | $855.51M | $860.36M |
| Intangibles | $386.15M | $397.90M | $406.96M | $360.62M | $337.27M |
| Total assets | $2.95B | $2.83B | $2.83B | $2.53B | $2.36B |
| Current liabilities | $135.83M | $126.79M | $164.94M | $404.20M | $375.26M |
| Long-term debt | $542.21M | $525.57M | — | — | — |
| Total debt | $542.21M | $525.57M | — | — | — |
| Total liabilities | $843.57M | $856.95M | $866.34M | $620.90M | $608.29M |
| Shareholders' equity | $2.11B | $1.97B | $1.96B | $1.91B | $1.75B |
| Net debt | -$23.81M | -$231.79M | — | — | — |
| Shares outstanding | 56.33M | 56.09M | 55.77M | 55.56M | 55.32M |
| Cash flow statement | |||||
| Operating cash flow | $117.42M | $175.39M | $113.92M | $172.08M | $119.02M |
| Capital expenditure | $23.52M | $25.68M | $36.22M | $84.83M | $67.09M |
| Free cash flow | $93.90M | $149.72M | $77.70M | $87.25M | $51.93M |
| Investing cash flow | -$298.47M | -$86.38M | -$123.28M | -$233.24M | -$221.17M |
| Financing cash flow | -$15.21M | -$82.90M | $248.96M | -$13.34M | $961,000 |
| Depreciation & amortization | $78.75M | $69.67M | $68.56M | $50.98M | $38.45M |
| Stock-based compensation | $32.60M | $48.07M | $25.57M | $27.32M | $27.50M |
| Share buybacks | $0 | $0 | $14.39M | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.